Health, and the University of California, Berkeley, Dr. Carter began his pharmaceutical career at Pharmacia Corporation, a pharmaceutical company, in 1993. He received a B.Sc. in
Biochemistry from the University of London, a Ph.D. in Biochemistry from the University of Cambridge, and an M.D. from the University of Miami School of Medicine. Dr. Carter currently serves as the chair of the scientific advisory board at
Bioniz Therapeutics. Dr. Carter has been chosen to serve on our Board due to his significant global experience in research and development in multiple therapeutic areas.
Rekha Hemrajani Ms. Hemrajani served as the president and chief executive officer of Aravive, Inc., a publicly traded
biotechnology company, from January 2020 to April 2020. Prior to Aravive, Ms. Hemrajani served as chief operating and financial officer of Arcus BioSciences, Inc., a publicly traded biopharmaceutical company, from March 2019 to September 2019.
From March 2016 to March 2019, Ms. Hemrajani served as chief operating officer for FLX Bio, a biotechnology company. From February 2015 to March 2016, Ms. Hemrajani was Chief Financial Officer and Senior Vice President of Business and
Financial Operations at 3-V Biosciences, a biotechnology company, with responsibility for corporate strategy, corporate development, finance, investor relations and G&A operations. From November 2013 to
January 2015, Ms. Hemrajani advised privately held companies on strategic corporate development and financing activities through her consulting firm, Ravinia Consulting. Previously, Ms. Hemrajani was Vice President, Head of Licensing and
Mergers and Acquisitions at Onyx Pharmaceuticals, a biotechnology company, and Vice President of Business Development at Exelixis, a biotechnology company. Ms. Hemrajani began her career in investment banking at firms such as Credit Suisse,
First Boston and Lehman Brothers, where she focused on the biopharmaceutical and healthcare sector. Ms. Hemrajani received her B.S. degree in Economics and Computer Science from the University of Michigan and her M.B.A. from the Kellogg
Graduate School of Management at Northwestern University. Ms. Hemrajani has been chosen to serve on our Board due to her executive and financial experience at multiple companies in the biopharmaceutical and biotechnology industries.
Thomas Woiwode, Ph.D. Dr. Woiwode has been with Versant Ventures, a healthcare investment firm, since 2002 in various
capacities, serving as a managing director since July 2014 and previously as a venture partner from June 2011 to July 2014. He has also served in a number of operating roles over this time, most recently as the chief operating officer of Okairos AG,
a biopharmaceutical company developing genetic vaccines for major infectious diseases, from April 2011 until May 2013, when Okairos was sold to GlaxoSmithKline plc. Prior to Okairos, Dr. Woiwode
co-founded EuroVentures, a wholly owned biotechnology incubator within Versant Ventures, and in this role, served as the founding chief business officer for three biotechnology companies created within
Versant. Prior to joining Versant Ventures, Dr. Woiwode served as a research scientist at XenoPort, Inc., a biotechnology company. Dr. Woiwode currently serves on the board of directors of several private companies and two other publicly
traded companies, Gritstone Oncology, Inc. and Passage BIO, Inc., and previously served on the board of directors of Audentes Therapeutics, Inc., a gene therapy company, and CRISPR Therapeutics AG. He received a B.A. in English and a B.S. in
Chemistry from the University of California, Berkeley and a Ph.D. in organic chemistry from Stanford University. Dr. Woiwode has been chosen to serve on our Board due to his educational background, his experience as a board member and senior
executive of biotechnology and pharmaceutical companies, and his experience as an investor in new life sciences companies.
CLASS II
DIRECTORS To continue in office until the 2022 Annual Meeting of Stockholders
Patrick Machado
Mr. Machado was a co-founder of Medivation, Inc., a biopharmaceutical company, and served as its chief business officer from 2009 to 2014 and as its chief financial officer from 2004 until his retirement
in 2014. From 1998 to 2001, Mr. Machado worked with ProDuct Health, Inc., a medical device company, as senior vice president, chief financial officer and earlier as general counsel. Upon ProDuct Healths acquisition by Cytyc Corporation, a
diagnostic and medical device company, he served as a consultant to Cytyc to assist with transitional matters from 2001 to 2002. Earlier in his career, Mr. Machado worked for Morrison & Foerster LLP, an international law firm, and for
the Massachusetts Supreme Judicial Court. Mr. Machado also serves as a member of the board of directors of Arcus Biosciences, Inc., Chimerix, Inc., Turning Point Therapeutics, Inc., Principia Biopharma Inc., and several private companies, and
previously served on the board of directors of Endocyte, Inc., Inotek Pharmaceuticals Corporation (now Rocket Pharmaceuticals, Inc.), Axovant Sciences, Inc. Medivation, Inc. and SCYNEXIS, Inc. Mr. Machado received a B.A. in German and a B.S. in
Economics from Santa Clara University and a J.D. from Harvard Law School. Mr. Machado has been chosen to serve on our Board due to his extensive experience dealing with the operational and financial issues of biopharmaceutical companies.
Leone Patterson Ms. Patterson was named our chief executive officer in October 2018. In connection with her promotion, our
Board appointed her as a member of the Board. Ms. Patterson had been serving as the interim president and chief executive officer since May 2018, and served as our president during October 2018, and from December 2019 to present. She also
served as our chief financial officer from June 2016 to April 2019. From March 2015 to June 2016, Ms. Patterson served as the chief financial officer of Diadexus, Inc., a diagnostics company, where she was responsible for overseeing the
companys finance function. Prior to that, Ms. Patterson was vice president and chief financial officer of Transcept Pharmaceuticals, Inc., a biopharmaceutical company, from June 2012 until it was acquired by Paratek Pharmaceuticals Inc.
in October 2014, where she
9.